Icahn School of Medicine at Mount Sinai Researchers Awarded $15.1 Million Grant to Explore Immune Rejection of Transplanted Organs

Link Type
Funded-research
Media Type
Article
Publish or Event Date
Link URL
https://www.mountsinai.org/about/newsroom/2023/icahn-school-of-medicine-at-mount-sinai-researchers-awarded-fifteen-million-grant-to-explore-immune-rejection-of-transplanted-organs
Research Institution
Icahn School of Medicine at Mount Sinai
Short Title
Icahn School of Medicine at Mount Sinai Researchers Awarded $15.1 Million Grant to Explore Immune Rejection of Transplanted Organs
Content Coordinator
Claudia Wair

Using the Microbiome to Protect Against Radiation Exposure

Link Type
Funded-research
Media Type
Article
Publish or Event Date
Link URL
https://www.umassmed.edu/news/news-archives/2023/06/using-the-microbiome-to-protect-against-radiation-exposure/
Research Institution
UMass Chan Medical School
Short Title
Using the Microbiome to Protect Against Radiation Exposure
Content Coordinator
Claudia Wair

TFF Pharmaceuticals Awarded $2.97 Million to Develop Universal Influenza Vaccine

Mpox Vaccine Trial for Adolescents, Children Begins at UM School of Medicine

Link Type
Funded-research
Media Type
Article
Publish or Event Date
Link URL
https://www.medschool.umaryland.edu/news/2023/Mpox-Vaccine-Trial-for-Adolescents-Children-Begins-at-UM-School-of-Medicine.html
Research Institution
University of Maryland School of Medicine
Short Title
Mpox Vaccine Trial for Adolescents, Children Begins at UM School of Medicine
Content Coordinator
Claudia Wair
Content Manager
Catey Laube Macdonald

Product Development Plans, Checklists, and Target Product Profiles

Product Development Services for Infectious Disease Research

Preclinical Services

The Division of Microbiology and Infectious Diseases (DMID) has built a comprehensive set of preclinical services to facilitate efforts to develop the next generation of vaccines, diagnostics and therapeutics for a broad array of bacterial, viral, fungal and parasitic pathogens, as well as novel control approaches for invertebrate vectors of public health importance. Through these in-kind services, eligible investigators worldwide get access to expertise, research materials, and state-of-the-art technologies at minimal or no charge.

Fund Your Product Development Research

Support for Infectious Disease Product Developers

Contact Your Program Officer to Discuss Opportunities

Contact DMID staff for more information about support mechanisms for product development programs.

Content Coordinator
Erin Zeituni
Mason Booth
Cynthia Rojas
Banner (Hero) Image
DMID Product Development Hero
Introduction

Mission Statement

The Division of Microbiology and Infectious Diseases (DMID) supports extramural research—basic through applied—to control and prevent diseases caused by virtually all human infectious agents except HIV (see HIV/AIDS Information for Researchers).

Overview

DMID supports product development research in a variety of ways. NIAID funding opportunities and solicitations can provide financial support for a specific research area. DMID also offers product development services for each stage of the development pathway. These services include a suite of preclinical programs that are available to the scientific community. The preclinical programs support in-kind studies, conducted by NIAID-funded contractors, to provide gap-filling information and de-risk the development process. Capabilities of the preclinical programs include synthesis and manufacturing, in vitro and in vivo testing, and safety and pharmacology studies. DMID also maintains numerous publicly available resources to help support research and development activities, such as repositories for sharing reagents and other materials. Finally, advanced development programs entering clinical trials can explore DMID’s clinical trial programs and resources. 

Highlights

Arms of scientist in gloves and lab-coat working with vials in a lab
Credit
NIAID

Diagnostics Development Services

NIAID’s Diagnostics Development Services program offers a comprehensive array of in-kind services to in vitro diagnostics developers to accelerate progress toward regulatory clearance and commercial launch.

Y-shaped monoclonal antibodies on a blue background with a monoclonal antibody in blue and yellow in the foreground approaching a green sphere representing a cell.
Credit
Adobe Stock

Plans and Profiles for Medical Countermeasures for Infectious Diseases

The generic product development plans and target product profiles provide guidance for the development of vaccines, small molecules, and monoclonal antibodies through early clinical evaluation.

NIAID Council Minutes January 30, 2023

The 203rd meeting of the National Advisory Allergy and Infectious Diseases Council (NAAIDC) convened virtually at 10:30 a.m. on Monday, January 30, 2023. Dr. Hugh Auchincloss, Acting Director, National Institute of Allergy and Infectious Diseases (NIAID) presided as chair.

Questions and Answers for Notice of Special Interest (NOSI)—Research on Early Allergy Determinants Using Biosamples from the SUNBEAM Birth Cohort

Subscribe to